Cargando…

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial

AIMS: Both left ventricular (LV) and left atrial (LA) dysfunction and remodelling contribute to adverse outcomes in heart failure with reduced ejection fraction (HFrEF). Danicamtiv is a novel, cardiac myosin activator that enhances cardiomyocyte contraction. METHODS AND RESULTS: We studied the effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voors, Adriaan A., Tamby, Jean‐François, Cleland, John G., Koren, Michael, Forgosh, Leslie B., Gupta, Dinesh, Lund, Lars H., Camacho, Albert, Karra, Ravi, Swart, Henk P., Pellicori, Pierpaolo, Wagner, Frank, Hershberger, Ray E., Prasad, Narayana, Anderson, Robert, Anto, Anu, Bell, Kaylyn, Edelberg, Jay M., Fang, Liang, Henze, Marcus, Kelly, Cynthia, Kurio, Gregory, Li, Wanying, Wells, Kate, Yang, Chun, Teichman, Sam L., del Rio, Carlos L., Solomon, Scott D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2020
Materias:	TREATMENT OF HFrEF
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689751/ https://www.ncbi.nlm.nih.gov/pubmed/32558989 http://dx.doi.org/10.1002/ejhf.1933

Ejemplares similares

The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta‐analysis of COMPANION and CARE‐HF
por: Cleland, John G.F., et al.
Publicado: (2022)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
por: Cooper, Trond J., et al.
Publicado: (2022)

Current and future use of neuromodulation in heart failure( )
por: Duncker, David, et al.
Publicado: (2022)

Neuromodulation in heart failure( )
por: Zannad, Faiez
Publicado: (2022)

Neuromodulation devices for heart failure( )
por: Dusi, Veronica, et al.
Publicado: (2022)

Sympathetic activation in heart failure( )
por: Gronda, E, et al.
Publicado: (2022)

Dear colleagues: enough with the men-only author panels
por: Van Spall, Harriette G C, et al.
Publicado: (2022)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Time for change
por: Zieroth, Shelley, et al.
Publicado: (2022)

Representation matters: a call for inclusivity and equity in heart failure clinical trials
por: Reza, Nosheen, et al.
Publicado: (2022)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe
por: Marx, Nikolaus, et al.
Publicado: (2022)

Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come
por: Piña, Ileana L, et al.
Publicado: (2022)

The effects of short‐term omission of daily medication on the pathophysiology of heart failure
por: Dovancescu, Silviu, et al.
Publicado: (2017)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Fukuta, Hidekatsu
Publicado: (2020)

What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure
por: Packer, Milton
Publicado: (2021)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle
por: Kooiker, Kristina B., et al.
Publicado: (2023)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
por: Bilak, Joanna M, et al.
Publicado: (2022)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Clinical importance of urinary sodium excretion in acute heart failure
por: Damman, Kevin, et al.
Publicado: (2020)

The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
por: Ráduly, Arnold Péter, et al.
Publicado: (2022)

Danicamtiv Enhances Systolic Function and Frank‐Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium
por: Shen, Shi, et al.
Publicado: (2021)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Development of a Psychologically Enhanced Interactive Online Intervention for Hazardous Drinking
por: Linke, Stuart, et al.
Publicado: (2008)

Intervention against Excessive Alcohol Consumption in Primary Health Care: A Survey of GPs' Attitudes and Practices in England 10 Years On
por: Wilson, Graeme B., et al.
Publicado: (2011)

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction
por: Parthasarathy, Hari K., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_r94rgj7oi84e6kbiu9u20f9827